Pfizer Inc. $PFE Stock Holdings Increased by Achmea Investment Management B.V.

Achmea Investment Management B.V. lifted its holdings in Pfizer Inc. (NYSE:PFE) by 4.1% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 324,790 shares of the biopharmaceutical company’s stock after purchasing an additional 12,888 shares during the quarter. Achmea Investment Management B.V.’s holdings in Pfizer were worth $7,873,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. GKV Capital Management Co. Inc. acquired a new position in Pfizer during the 1st quarter valued at about $27,000. Curio Wealth LLC boosted its holdings in shares of Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,098 shares in the last quarter. Bayforest Capital Ltd acquired a new position in shares of Pfizer during the first quarter valued at approximately $28,000. Harbor Asset Planning Inc. acquired a new position in shares of Pfizer during the second quarter valued at approximately $29,000. Finally, WPG Advisers LLC bought a new stake in Pfizer during the first quarter worth approximately $35,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of NYSE:PFE opened at $24.92 on Friday. The company’s fifty day moving average is $24.75 and its two-hundred day moving average is $24.34. The company has a market cap of $141.68 billion, a P/E ratio of 13.26, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $27.69. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.79 by $0.08. The business had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s payout ratio is 91.49%.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $30.00 price target on shares of Pfizer in a research note on Friday, October 31st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Citigroup lifted their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $28.18.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.